Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

BACKGROUND: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. OBJECTIVE: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Comi, Giancarlo, Alroughani, Raed, Boster, Aaron L, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard AL, Sharrack, Basil, Singer, Barry A, Vermersch, Patrick, Wiendl, Heinz, Ziemssen, Tjalf, Jacobs, Alan, Daizadeh, Nadia, Rodriguez, Claudio E, Traboulsee, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720359/
https://www.ncbi.nlm.nih.gov/pubmed/31762387
http://dx.doi.org/10.1177/1352458519888610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720359/
https://www.ncbi.nlm.nih.gov/pubmed/31762387
http://dx.doi.org/10.1177/1352458519888610

Ejemplares similares